Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
12:02pm, Monday, 13'th Nov 2023
Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
Novo Nordisk's Wegovy could reduce heart risks by 20%
10:56am, Monday, 13'th Nov 2023
According to a new trial study, Novo Nordisk's (NVO) weight loss drug Wegovy may have the added benefit of cutting down risks tied to cardiovascular complications by at least 20%. Yahoo Finance Live m
Wegovy predicted to become huge drug as weight loss benefits confirmed
10:22am, Monday, 13'th Nov 2023
Novo Nordisk (NYSE:NVO) did not disappoint with the latest trial data update of its blockbuster diabetes drug Wegovy, according to analysts at US bank Citi. Full results from the SELECT trial released
Better Buy Now: Novo Nordisk vs. Eli Lilly
06:17am, Monday, 13'th Nov 2023
Novo Nordisk's weight management blockbuster produced some surprising results for its ability to reduce patients' risk of a second heart attack. The Food and Drug Administration recently approved Eli
Novo's Wegovy Trial Shows Heart Benefit in Obesity Patients
06:04am, Monday, 13'th Nov 2023
Novo Nordisk A/S revealed details from a key study backing the use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and deaths in obesity patients with a history of cardiovascular dis
Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss
04:26am, Monday, 13'th Nov 2023
Novo Nordisk shares rose 3.3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not sol
Novo Nordisk's Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds
08:47am, Saturday, 11'th Nov 2023
Novo Nordisk's NVO, +1.16% popular weight-loss drug Wegovy significantly cut the risk of heart attack, stroke or death due to cardiovascular disease in people who do not have diabetes, according to ne
Novo Nordisk says Wegovy heart benefits due to more than weight loss
08:32am, Saturday, 11'th Nov 2023
Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical me
Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
08:30am, Saturday, 11'th Nov 2023
The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
11:13am, Friday, 10'th Nov 2023
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is Approved
10:10am, Friday, 10'th Nov 2023
Novo has struggled to keep up with booming demand for its weight loss drug and said it could be years until it or its rivals are able to satisfy the growing market.
Novo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand production
10:02am, Friday, 10'th Nov 2023
Novo Nordisk NVO, -1.36% said Friday that it will invest more than $6 billion to expand manufacturing facilities in Kalundborg, Denmark, where the company produces GLP-1 drugs such as Wegovy as well a
Drugmaker Novo Nordisk seeks obesity, diabetes 'bolt-on' deals
06:05am, Friday, 10'th Nov 2023
Novo Nordisk wants to buy more companies with drugs in early- to mid-stages of development through "bolt-on" deals of up to a few billion dollars, CEO Lars Fruergaard Jorgensen told Reuters on Friday.
Novo Nordisk unveils $6bn investment plans
03:06am, Friday, 10'th Nov 2023
Europe's largest pharma company, Novo Nordisk (NYSE:NVO), has unveiled plans for a significant investment of more than $6 billion to cater to the increasing demand for its Wegovy weight-loss treatment
Novo Nordisk to invest $6 bln in Denmark expansions
01:42am, Friday, 10'th Nov 2023
Novo Nordisk said on Friday it will invest more than 42 billion Danish crowns ($6 billion) from 2023 onwards to expand its manufacturing facilities in Denmark for the current and future product portfo
